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Abstract: Targeting protein–protein interactions (PPI) is an emerging field in drug discovery. 
Dimerization and PPI are essential properties of human immunodeficiency virus (HIV)-1 
proteins, their mediated functions, and virus biology. Additionally, dimerization is required for 
the functional interaction of HIV-1 proteins with many host cellular components. In this study, 
a bimolecular fluorescence complementation (BiFC)-based screening assay was developed that 
can quantify changes in dimerization, using HIV-1 viral protein R (Vpr) dimerization as a “proof 
of concept.” Results demonstrated that Venus Vpr (generated by BiFC Vpr constructs) could 
be competed off in a dose-dependent manner using untagged, full-length Vpr as a competitor 
molecule. The change in signal intensity was measured quantitatively through flow cytometry 
and fluorescence microscopy in a high content screening assay. High content imaging was 
used to screen a library of small molecules for an effect on Vpr dimerization. Among the 
tested molecules, a few of the small molecules demonstrate an effect on Vpr dimerization in a 
dose-dependent manner.
Keywords: BiFC, protein–protein interaction, HIV-1 Vpr, dimerization, drug targets
Introduction
Protein–protein interactions (PPI) are essential for many cellular functions, including 
cancer and host pathogen interactions.1 Thus, a variety of methods have been developed 
to evaluate direct PPI in vitro and in vivo for future targeting strategies.2–4 In vitro 
methods such as copurification and affinity precipitation assays require the removal 
of proteins from their native environment and are not compatible with high through-
put screening (HTS). A number of cell-based assay technologies that are compatible 
with HTS have been applied to PPI targets including yeast and mammalian 2 hybrid 
assays, fluorescence resonance energy transfer, bioluminescence resonance energy 
transfer (BRET), positional biosensors, and protein–fragment complementation assays 
(PCA).5 The visualization and quantification of direct protein interactions within living 
cells provide two important advantages over other methods – the protein partners are 
expressed in their normal cellular environment, and their subcellular localization can 
be determined. Bimolecular fluorescence complementation (BiFC) approaches use 
protein interaction partners expressed as chimeras with fragments of a fluorescent 
protein. BiFC is based on the formation of a fluorescent complex by fragments of 
fluorescent proteins for which association is facilitated by the interaction between the 
proteins fused to these fragments. BiFC analysis has been used successfully to study 
the direct interaction of many different proteins in different cell types and organisms.6–9 
Recent studies have also shown that BiFC analysis can be used for HTS to assess the 
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effects of small molecules on protein complexes, providing 
a method to measure spatial and temporal changes in protein 
complexes that are a response to drugs.10
Dramatic improvements in treating human immuno-
deficiency virus-type 1 (HIV-1) infected individuals have 
been attained with highly active antiretroviral therapy. Most 
antiretroviral treatment regimes, however, fail to provide 
long-term suppression of viral replication and therefore do 
little to control disease progression.11–14 This has prompted 
investigators to explore small molecule inhibitors that target 
conserved functions of other viral proteins as well as viral-
host interactions. Most of the HIV-1 viral proteins (Gag, 
Nef, viral protein R [Vpr], reverse transcriptase, integrase, 
Rev, Env and protease) form dimers and/or oligomers that 
are critical to their functions in the viral life cycle.15–20 
Darunavir, a protease inhibitor, was found to also inhibit 
protease dimerization; it has also shown decreased escape 
mutant formation compared to other protease inhibitors.21 
Thus, viral protein dimerization is a viable target in HIV-1 
and can provide additional potent antivirals. To test this 
hypothesis and to develop a high-throughput cell-based 
screening platform, we used HIV-1 Vpr as a “proof of 
concept” molecule and evaluated a method to block protein 
dimerization and/or PPI. Furthermore, there are no Food 
and Drug Administration-approved antivirals that target this 
protein, despite evidence that HIV-1 Vpr is implicated in 
pathogenesis;22,23 however, studies are in progress to target 
HIV-1 Vpr by many investigators.24–28
HIV-1 encoded Vpr, a nonstructural protein, is incorpo-
rated into the virus particle and possesses several character-
istic features that are known to play important roles in HIV-1 
replication. Biochemical and nuclear magnetic resonance 
studies suggest that Vpr has three alpha helices connected 
by loops that interact with each other to form dimers and 
oligomers upon expression.29–32 Many of the functions of 
Vpr in the cell are carried out by virion-associated Vpr 
(similar to de novo synthesized Vpr), suggesting that the 
incorporation of Vpr into virus particles is important in 
HIV-1 biology.33–35 In infected cells, Vpr is primarily pres-
ent as dimers, though at higher concentrations it is known 
to form trimers and oligomers.36,37 Preliminary studies on 
Vpr dimerization using a BiFC assay system show that 
dimerization-defective Vpr molecules fail to incorporate 
into virus particles, suggesting that Vpr dimerization is 
essential for virion incorporation, interaction with host 
cellular proteins, and downstream functions of Vpr.38 The 
focus of this report is first to develop an assay to measure 
changes in Vpr dimerization and, secondly, to screen two 
libraries for inhibitors of Vpr dimerization. Results indicate 
that BiFC-based high content cell-based screening provides 
a measureable readout that will be useful to screen com-
pound libraries. Two small libraries were screened, one of 
overlapping Vpr peptides, and another of leucine rotamers 
designed to mimic alpha helices. Together, these studies 
validate the usefulness of this assay and potential for future 
drug screening.
Materials and methods
Cell lines and plasmids
HeLa cell lines were grown in Dulbecco’s modified Eagle 
medium (Gibco®; Life Technologies, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (HyClone; 
Thermo Fisher Scientific, Inc, Waltham, MA, USA), 1% 
penicillin–streptomycin (Invitrogen; Life Technologies), 
and 1% L-glutamine (Invitrogen; Life Technologies). The 
Venus-Vpr chimeric constructs were generated as described.39 
Briefly, sequences encoding the amino (residues 1–173; 
referred to as VN) or carboxyl (residues 155–238; referred to 
as VC) fragments of Venus fluorescence protein were fused to 
the N terminus of HIV-1 Vpr via a six alanine linker. Venus-
Vpr refers to cells expressing both VC-Vpr and VN-Vpr via 
transient transfection. HIV-1 Vpr containing Flag-tag was 
used as “untagged” Vpr in competition assays.
Vpr peptides and leucine rotamers
HIV-1 consensus B VPR peptides (15 amino acids in 
length, with eleven amino acid overlaps) were obtained 
from the National Institutes of Health (NIH) AIDS Reagent 
repository and dissolved according to the datasheet for these 
peptides. Vpr peptides were dissolved either in phosphate 
buffered saline (PBS) (at 10 µg/mL) or in dimethyl sulfoxide 
(DMSO) (at 1 µg/mL) based on the information provided 
in the Vpr peptide datasheets from NIH, ARRP (AIDS 
Research and Reagent program). Leucine rotamers were 
synthesized as small molecular weight mimics of α-helices 
of proteins and dissolved in DMSO for further use.
Transfection
Cells were transfected with equal quantities of VN-Vpr and 
VC-Vpr using the PolyJet reagent as suggested (SignaGen 
Laboratories, Rockville, MD, USA). Five hours post-
transfection in screening assays, cells were trypsinized and 
replated into a 96-well plate at a density of 45,000 cells/mL 
and treated with Vpr peptides or compounds diluted in an 
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appropriate solvent in triplicate. Twenty-four hours posttreat-
ment, cells were fixed and analyzed.
Western blot and immunofluorescence
Cells were seeded on six-well plates and transfected with a 
total of 2 µg of plasmid (combinations of Venus-Vpr, Vpr-flag, 
and empty vector). Cells were lysed, and protein levels were 
quantitated with a bicinchoninic assay (Pierce Biotechnology, 
Inc, Rockford, IL, USA). Samples were transferred to a polyvi-
nylidene fluoride membrane (EMD Millipore, Billerica, MA, 
USA) and probed for Flag, HA-tag, or tubulin using mono-
clonal antibodies. Membranes were developed using enhanced 
chemiluminescence substrate (Pierce Biotechnology, Inc). For 
immunofluorescence, cells were transfected with a total of 2 µg 
of plasmid (combinations of Venus Vpr, Vpr-Flag, and empty 
vector) using PolyJet. Eighteen hours post-transfection, cells 
were fixed and stained with anti-HA and anti-Flag antibody.40 
Cell nuclei were stained with Hoescht 33342 (Life Technolo-
gies, Grand Island, NY, USA). Fluorescence was detected using 
an Olympus Fluoview 500 upright microscope (Olympus, 
Center Valley, PA, USA) with appropriate filters. Spot intensity 
quantification was performed using MetaMorph II software 
(Molecular Devices, LLC, Sunnyvale, CA, USA).
High content imaging analysis
Cells were transfected as described above, f ixed, and 
cell nuclei were stained with Hoescht 33342. Cells were 
stored in PBS until automated fluorescence microscopy 
analysis with the ArrayScan VTI HCS Reader imaging 
cytometer (Thermo Scientific Cellomics; Thermo Fisher 
Scientific, Inc, Waltham, MA, USA). Data were collected 
in the fluorescein isothiocyanate, tetramethylrhodamine-
5-(and-6)-isothiocyanate (TRITC), and 4′,6-diamidino-2-
phenylindole dihydrochloride channels, and analyzed using 
the BioApplications platform (Thermo Fisher Scientific, Inc). 
Background fluorescence was eliminated through comparison 
of fluorescein isothiocyanate (FITC) and TRITC channel 
intensities, and dying cells were excluded based on small 
nuclear area using the standard protocols developed by the 
Drug Discovery Institute of University of Pittsburgh. The 
number of viable cells per field was recorded for each well 
and used to assess comparative cytotoxicity. Viable cells were 
analyzed for mean nuclear BiFC intensity. The signal-to-noise 
ratio (S/N) was calculated as:
 S/N
Mean signal Mean background




The Z′ factor measures the separation band using a com-
bination of the variability and the difference in mean signal 
between the positive and negative controls.41 The Z factor 
(Z′) was calculated as:
 Z
3SD of sample 3SD of control







All Vpr peptides and small molecules were tested in tripli-
cate on each plate. The replicate wells were averaged, and 
the average between these three wells was used to normalize 
the data between plates. Based on criteria published by the 
University of Pittsburgh Drug Discovery Institute, Z-scores 
were used to normalize the data across multiple plates.42 





where x is the value to be normalized, µ is the mean, and σ 
is the SD of the mean. The mean was defined as the aver-
age across all replicates of the appropriate solvent-treated, 
transfected control on a single plate. To compare between 
plates, the Z-scores from individual plates were averaged 
for each small molecule. Due to the exploratory nature of 
the assay, the hit threshold was set at one standard deviation 
from the mean.
Results
Kinetics of protein expression
BiFC-based reconstitution of the Venus fluorophore is 
irreversible. Therefore, it was necessary to understand the 
kinetics of protein expression in order to time the addition 
of dimerization inhibitors before the expressed proteins 
form dimers and/or oligomers. To determine the speed of 
transfected protein expression, cells were cotransfected with 
equal amounts of VN-Vpr and VC-Vpr plasmid (referred as 
Venus-Vpr), collected at various times post-transfection, 
and assessed by Western blot (Figure 1A). Vpr expression 
was detected as early as 6 hours post-transfection in HeLa 
cells; by 12 hours post-transfection, the proteins levels were 
saturated in cell lysate (Figure 1A). Simultaneous measure-
ment of BiFC within the same culture indicates that only 
10% of cells are BiFC-positive and the percentage increases 
drastically to .40% by 12 to 15 hours post-transfection, 
remaining steady thereafter (Figure 1B). The delay between 
protein expression and BiFC fluorescence detection is likely 
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due to the maturation time needed for the reconstitution of 
the Venus molecule.43
Competition assay
In order to function as a screening tool, the BiFC system 
must be able to quantitatively detect changes in dimeriza-
tion levels. In the absence of a known positive control, 
we used a competition assay to detect a decrease in Vpr 
dimerization through the BiFC signal. Reconstitution of 
the fluorophore by dimerization of the Venus-Vpr fusion 
proteins was competed off by cotransfection of increasing 
quantities of untagged, full-length Vpr (Vpr-Flag), and 
BiFC signal was measured. The input of Venus-Vpr was 
held constant to allow for comparison among the different 
ratios of Venus-Vpr to competitor. Increasing amounts of 
untagged Vpr, up to a maximum ratio of 1:8 Venus-Vpr to 
Vpr-Flag, were assessed at 18 hours post-transfection for 
their effect on BiFC  fluorescence. Results indicate the mean 
fluorescence intensity (MFI) exhibits a linear decrease as 
levels of competitor Vpr-flag increase. At the 1:8 ratio, 
the MFI decreased by 40% compared to Venus-Vpr alone 
(Figure 2). To verify the level of Venus-Vpr protein expres-
sion in these samples, we performed a Western blot on 
cell lysates from these cotransfected cells, and the results 
indicated no change in Vpr fusion protein expression (data 
not shown). Flow cytometry gates were set to capture all 
BiFC positive cells, independent of intensity. No significant 
change was observed in the percentage of BiFC positive 
cells (data not shown), which suggests that transfection 
efficiency was not affected by the addition of competitor 
Vpr-flag plasmid.
We next assessed the decrease in BiFC signal intensity 
using immunostaining followed by imaging using a confocal 
microscope. HeLa cells cotransfected with Venus-Vpr alone 
or with Vpr-Flag at a 1:8 ratio were fixed and stained with 
anti-Flag antibody (Figure 3). A visible decrease in BiFC 
fluorescence intensity was observed in cells cotransfected 
with Venus-Vpr and Vpr-flag (bottom panel) compared 
with Venus-Vpr and vector deoxyribonucleic acid (DNA) 
(middle panel). The average intensity of the BiFC signal 
in the nucleus for Venus-Vpr transfection without Vpr-flag 
was 223.34 ± 47.09. For Vpr-flag cotransfected cells, five 





























Figure 1 Vpr expression kinetics and generation of BiFC in transfected cells.
Notes: Cells were cotransfected with equal amounts of Vn-Vpr and VC-Vpr plasmids. Hours post-transfection, cells were collected, split into two halves, and used for 
further analysis. (A) Cells were lysed and analyzed via Western blot using anti-HA antibody to detect Vpr expression. Tubulin was used as loading control. (B) Cells were 
fixed and analyzed via flow cytometry to detect the percentage of BiFC-positive cells. Results represent one of three independent experiments.
Abbreviations: Vpr, viral protein R; BiFC, bimolecular fluorescence complementation; VN-Vpr, Vpr fused to N-terminus of Venus protein; VC-Vpr, Vpr fused to C-terminus 


































Figure 2 Competition assay to detect the loss of BiFC signal generated by Vpr 
dimerization.
Notes: Cells were transfected with a constant amount of Venus-Vpr plasmid with 
increasing concentrations of untagged Vpr plasmid. DnA concentration and volume 
were normalized using empty vector DnA. Eighteen hours post-transfection, cells 
were collected and analyzed by flow cytometry. Results represent the mean of four 
independent experiments, and data from each experiment were normalized to the 
1:0 (Venus Vpr: Untagged Vpr) sample.
Abbreviations: BiFC, bimolecular fluorescence complementation; Vpr, viral 
protein R; DnA, deoxyribonucleic acid.
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analyzed to generate an average pixel intensity of 141.10 ± 
22.85. When normalized to the Venus-Vpr transfection, there 
is a 37% decrease in pixel intensity. These results show that a 
decrease in dimerization can be quantified at similar levels by 
both flow cytometry through MFI of BiFC positive cells, and 
fluorescence microscopy through average pixel intensity.
Analysis of peptide library
A library of overlapping Vpr peptides was screened by 
high content imaging analysis for its ability to block Vpr 
 dimerization. Z-scores were calculated and the average 
scores from four repetitions were plotted (Figure 4A). While 
six peptides (p4, p5, p7, p14, p16, and p19) showed greater 
than one SD from the mean BiFC signal intensity, all of the 
SDs overlapped the variability window and thus could not 
definitely be considered a deviation from the mean. It is 
interesting to note that four of these peptides (p4, p5, p7 and 
p19) showed an increase, suggesting enhanced dimerization/ 
oligomerization, whereas p14 and p16 showed a negative 
impact on dimerization. Next, we assessed the toxicity of 
Vpr peptides, as Vpr peptides in certain helices are known 
to induce apoptosis and cell death.38 Results presented in 
Figure 4B show the average number of cells per field for 
each peptide treatment measured using the HCS tool-based 
cell viability. The peptides dissolved in PBS (p1–9, p11, 
p17–22) were well tolerated when compared to the PBS 
vehicle control; however, with the exception of p12, the pep-
tides dissolved in DMSO exhibited significant cytotoxicity 
compared to the DMSO vehicle control. The DMSO vehicle 
control averaged 25 cells per field, whereas peptides 10, 13, 
14, 15, and 16 averaged between eight and twelve cells per 
field, suggesting high toxicity. Further analysis indicates that 
these peptides are part of the third helical domain and the 
C-terminal domain of Vpr, both of which have been impli-
cated in Vpr-mediated cell death and apoptosis.44,45 Together, 
these results did not identify a Vpr inhibitory peptide, but 
rather they identified positive regulators of Vpr dimeriza-
tion, suggesting these regions of the Vpr molecule might be 
involved in forming higher orders of oligomerization.
Analysis of leucine rotamer library
A leucine rotamer library, containing 45 small molecules, 
was screened using high content image analysis for effects on 
Vpr dimerization measured by BiFC signal (Figure 5A). Of 
the 45 leucine rotamers screened, three had greater than one 
SD separation from the mean. Rotamer 14 had a separation 
of +2.23 SDs from the transfected control, indicating that it 
increased the mean BiFC intensity in the nucleus. Rotamer 
Vpr-Flag





Figure 3 Fluorescence intensity of BiFC generated by Venus-Vpr in the presence of competitor untagged Vpr.
Notes: Cells were seeded onto cover slips and transfected with Venus-Vpr plasmids, Vpr-Flag, or Venus-Vpr and Vpr-Flag. Cells were fixed 18 hours post-transfection, 
stained with Cy5-conjugated Flag M5 antibody to detect the Vpr competitor molecule. Cells were viewed under confocal microscope at 60X magnification. Blue, DAPI to 
stain the nucleus; green, BiFC signal to visualize Venus-Vpr; red, Flag-Cy5 signal to detect the competitor Vpr molecule.
Abbreviations: BiFC, bimolecular fluorescence complementation; Vpr, viral protein R; DAPI, 4′,6-diamidino-2-phenylindole, dihydrochloride.
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36 also increased nuclear BiFC signal, but was less potent 
 (separation of +1 SDs from the transfected control) than 
rotamer 14. Although three rotamers (20, 24, and 32) decreased 
the nuclear BiFC intensity by more than 1 SD from the mean, 
the level of variation for 20 and 24 are high; in  contrast, 
rotamer 32 decreased the nuclear BiFC signal by greater than 
1 SD. Rotamer 32 showed a separation of –1.37 SDs from the 
mean. Based on the initial screen, rotamers 14, 32, and 36 were 
rescreened at higher concentrations (10 µM). The negative 
effect of rotamer 32 remained the same at both concentra-
tions (data not shown). The positive effect of rotamer 14 on 



















































Figure 4 Ability of Vpr peptides to interfere with Vpr dimerization.
Note: (A) Vpr peptides were screened for an effect on nuclear BiFC fluorescence using high content imaging. Cells transfected with Venus-Vpr plasmids were treated with 
Vpr peptides or vehicle controls (DMSO or PBS) and assessed for BiFC signal as described in methods. Data were normalized to the solvent-appropriate control cells. The 
average and standard deviation across four independent experiments were calculated and plotted. (B) The average number of viable cells per field, after excluding cells 
for morphology and nuclear size using the image software, were recorded for each well (based on the average of .20 fields per well). The figure represents one of four 
independent experiments.
Abbreviations: Vpr, viral protein R; BiFC, bimolecular fluorescence complementation; PBS, phosphate buffered saline; DMSO, dimethyl sulfoxide; TF, transfection.
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At a 1 µM concentration, rotamer 36 treatment resulted in a 
slight increase in nuclear BiFC fluorescence; however, at a 
10 µM concentration, a negative effect on nuclear BiFC fluo-
rescence was observed. Next, the cytotoxicity of the leucine 
rotamers was assessed at a 1 µM  concentration.  Rotamers 
2, 4, 15, 41, 44, and 45 had cell counts 20% lower than the 
DMSO-treated control  (Figure 5B). Interestingly, eleven 
rotamer treatments, including rotamer 36, displayed cell 
counts over 20% higher than the control. Overall, transfected 
cells tolerated leucine rotamers well at the concentration used 
for high content screening analysis.
Discussion
Advances in the study of PPI in the last 10 years have 
opened up promising new lines of research in the field of 
therapeutics.26,46–48 One specific type of PPI, the formation of 
dimers, has been identified as a drug target in almost all HIV 
proteins.49–55 Our laboratory had previously shown that a pair 
of BiFC plasmids for Vpr produce Vpr dimers that restore the 
fluorescent molecule when cotransfected.39 Here we assessed 
whether this BiFC system could be used to detect a decrease 
in Vpr dimerization using a competition assay; a similar 
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Figure 5 Ability of leucine rotamer library to inhibit Vpr dimerization measured by BiFC signal.
Note: (A) Small molecules (leucine rotamers) were screened for their ability to interfere with Vpr dimerization measured by BiFC fluorescence using high content 
imaging. Cells transfected with Venus-Vpr plasmids were treated with leucine rotamer library (1 µM) or vehicle control (DMSO) and assessed for BiFC signal. Data was 
normalized to vehicle exposed transfected cells using Z-score methods. The average and standard deviation from two independent experiments were calculated and plotted. 
(B) The average number of viable cells per field, after excluding cells for morphology and nuclear size, were recorded for each well (based on the average of .20 fields per 
well) using the image software. Figure represents one of two independent experiments.
Abbreviations: Vpr, viral protein R; BiFC, bimolecular fluorescence complementation; TF, transfection; PBS, phosphate buffered saline; DMSO, dimethyl sulfoxide.
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transcription factors.56 Using a triple plasmid transfection 
strategy, we cotransfected the two Venus fragment-tagged 
Vpr plasmids and an untagged Vpr expression plasmid or vec-
tor control. At higher input levels of untagged Vpr, a decrease 
in the MFI, but not the percentage of BiFC-positive cells, 
was observed. This indicated that the transfection efficiency 
was the same among the samples, but that triple plasmid 
transfected cells fluoresce less brightly than cells transfected 
with DNA vector control. This suggests that untagged Vpr 
can compete for the formation of dimers in a dose-dependent 
manner. The MFI decreases as the concentration of untagged 
Vpr increases, indicating the feasibility of this system as a 
screening tool. Surprisingly, a slight increase in both the 
percentage of BiFC-positive cells and the MFI was seen 
between the 1:1 ratio of Venus-Vpr to competitor and the 
Venus-Vpr alone. Vpr is known to form dimers, trimers, and 
hexamers in a concentration-dependent manner;31 therefore, 
one possible explanation for the increased MFI is the forma-
tion of higher-order oligomers.
Imaging-based high content screening using automated 
fluorescence microscopy has several advantages over other 
screening methods. The major advantage is the lack of 
manipulation of the cells, which reduces the background 
signal in addition to giving us the ability to incorporate 
other parameters such as toxicity, mitochondrial function, 
and subcellular distribution of the target protein(s). Another 
important feature of a high content screen is the Z-score. 
Z-scores present the difference between a value and the 
control in terms of SDs from the control mean. The hit 
threshold of greater than 1 SD from the mean was chosen 
for three reasons. First, this is a cell-based screen, and the 
library members may be impermeable to cells. Secondly, the 
final concentrations of small molecules that we are applying 
to cells are in the low micromolar range. In vitro HTS assays 
typically discover hits in the high micromolar or millimolar 
range. The low concentration of the small molecule treatment 
may reduce the magnitude of the result. Thirdly, there is no 
known inhibitor of Vpr dimerization to use as a positive 
control, and thus no effective dose is available for reference 
and/or calibration.
The screen of the peptide library yielded five compounds 
whose Z-scores were greater than 1 SD away from the mean, 
but all five had large margins of error that extended into the hit 
threshold. The screen of the leucine rotamer library yielded 
three compounds with Z-scores greater than 1 SD from the 
mean whose error bars did not cross the hit threshold. These 
rotamers (14, 32, and 36) were assessed at a tenfold higher 
dilution (10 µM) to further evaluate the dose-dependent 
effect. Rotamers 32 and 36 displayed 67% toxicity at this 
level, but rotamer 14 remained relatively nontoxic. Rotamer 
32 had a negative effect on BiFC intensity, but increasing 
the concentration of 32 did not increase the magnitude of the 
effect. Interestingly, 14 showed increased BiFC fluorescence 
compared to the control, and it responded in a dose-dependent 
manner when tested at a higher concentration. While this 
was not the desired outcome of the screen, a compound 
that increases dimerization of Vpr could have laboratory 
relevance. Vpr tagged with enhanced green fluorescent pro-
tein is used to create fluorescently tagged virus particles for 
studies on viral entry and uncoating. If an increase in Vpr 
dimerization/oligomerization results in increased incorpora-
tion into the viral particle, this small molecule could be used 
to increase the overall intensity of fluorescent virions, which 
would aid in imaging studies.
Taken together, a system to detect the dimerization of HIV-1 
Vpr was developed and assessed. It is capable of measuring 
changes in fluorescence intensity through both flow cytometry 
and high content imaging. We concluded that BiFC is a valid 
system for detecting interference with dimerization and moved 
to a small-scale high content screen. Though we selected Vpr 
dimerization as a “proof of concept” molecule in this report, 
BiFC-based HCS can be applied to other HIV-1 viral pro-
teins such as protease and Gag, as well as viral–host protein 
interactions. Most HIV viral proteins (Gag, Nef, RT, Vpr, and 
protease) form dimers and/or oligomers, and this unique feature 
is important for their functions in virus biology.15–19,31 Further-
more, drug resistance mutations within the oligomeric domains 
of HIV-1 proteins are lethal to their functions, thus disrupting 
such protein–protein interactions with small molecules will 
provide probe compounds with strong antiviral effects that are 
less susceptible to resistance development.
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